Hyperammonemia: Clinical Trials

5 trials for Hyperammonemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 5 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Completed 5
Phase 11Completed 1

Follow Hyperammonemia: new trials by email Literature Review of Hyperammonemia trials Research Report on Hyperammonemia

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PK Profile and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia
TNP-2092 capsules, Placebo - Hyperammonemia
Phase 1 / Phase 2CompletedTenNor Therapeutics (Suzhou) Limited362020-08-272025-04-25
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
ornithine phenylacetate, placebo intravenous infusion - Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
Phase 2CompletedOcera Therapeutics, Inc.2312014-01-072021-09-16
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
Carbaglu, Placebo - Propionic Acidemia, Type I and/or Type II, Methylmalonic Acidemia
Phase 2CompletedMendel Tuchman352012-09-012021-02-15
Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders
HPN-100, NaPBA - Urea Cycle Disorders
Phase 2CompletedAmgen172010-03-012024-07-11
Pilot Study For Hypothermia Treatment In Hyperammonemic Encephalopathy In Neonates And Very Young Infants
Therapeutic Hypothermia, Standard of Care Therapy - Urea Cycle Disorders, Organic Acidemias
Phase 2CompletedUta Lichter-Konecki52007-08-012015-06-01

Narrower conditions

Carbamoyl-Phosphate Synthase I Deficiency Disease (2)  ·  Methylmalonic acidemia (2)  ·  Ornithine Carbamoyltransferase Deficiency Disease (2)  ·  Propionic Acidemia (2)  ·  Urea Cycle Disorders, Inborn (2)  ·  Argininosuccinic Aciduria (1)  ·  Brain Diseases (1)  ·  Brain Edema (1)  ·  Citrullinemia (1)  ·  Coma (1)  ·  Fibrosis (1)  ·  Hepatic Encephalopathy (1)  ·  Lethargy (1)  ·  Seizures (1)

Broader conditions

Pathologic Processes (5)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Brain Diseases, Metabolic (4)  ·  Central Nervous System Diseases (4)  ·  Metabolic Diseases (4)  ·  Nervous System Diseases (4)  ·  Nutritional and Metabolic Diseases (4)  ·  Amino Acid Metabolism, Inborn Errors (3)  ·  Brain Diseases (3)  ·  Brain Diseases, Metabolic, Inborn (3)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)  ·  Genetic Diseases, Inborn (3)  ·  Metabolism, Inborn Errors (3)  ·  Genetic Diseases, X-Linked (2)  ·  Mitochondrial Diseases (2)

Interventions

Continuous Renal Replacement Therapy (1)  ·  Cool-Down Exercise (1)  ·  Cryotherapy (1)  ·  Dialysis (1)  ·  Hypothermia, Induced (1)  ·  Renal Dialysis (1)  ·  TNP-2092 (1)  ·  carglumic acid (1)  ·  glycerol phenylbutyrate (1)  ·  ornithine phenylacetate (1)

Sponsors

Amgen (1)  ·  Mendel Tuchman (1)  ·  Ocera Therapeutics, Inc. (1)  ·  TenNor Therapeutics (Suzhou) Limited (1)  ·  Uta Lichter-Konecki (1)

Countries

United States (4)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  China (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Estonia (1)  ·  France (1)  ·  Germany (1)  ·  Hungary (1)  ·  Israel (1)  ·  Italy (1)

Top investigators

Mendel Tuchman, MD (1)  ·  Uta Lichter-Konecki, MD, PhD (1)  ·  Yanhua Ding, MD (1)

Results publications

PMID 22961727, PMID 24144944, PMID 33006765, PMID 33069881, PMID 34786649, PMID 35238476